Eduardo Ruman (In Memoriam)
Diretor-Presidente
Administrativo e Empreendedor
Denise Ruman
MTB - 0086489
JORNALISTA RESPONSÁVEL
The Biggest and Best International Newspaper for World Peace
BRANCH OFFICE of PACIFIST JOURNAL in LATIN AMERICA
Founder, President And International General Chief-Director / Fundadora, Presidente e Diretora Geral Internacional :  Denise Ruman - MTB: 0086489 / SP-BRAZIL
Local Chief-Director - Brazil / Diretora-Chefe Local - Brasil :  Denise Ruman
Mentor do Jornal / Mentor of the Newspaper  :  José Cardoso Salvador (in memoriam)
Mentor-Director / Mentor-Director  :  Mahavátar Babají (in memoriam)

Saúde / 12/07/2021

HEALTH TECHNOLOGY

Oxford Begins Testing HIV Vaccine on Volunteers

0 votes
Oxford Begins Testing HIV Vaccine on Volunteers

Fonte Herald

The University of Oxford has started a Phase 1 clinical trial in the UK of an HIV vaccine.

The HIVconsvX vaccine will initially be used in volunteers against a wide range of HIV-1 variants, making it potentially applicable to strains of the virus in any region of the planet.

The trial aims to assess the safety, tolerability and immunogenicity of the HIVconsvX vaccine.

Vaccination

To test, the University of Oxford has initiated vaccination, phase 1 of HIV-Core 0052, in thirteen healthy, HIV-negative adults, ages 18-65 and considered not to be at high risk of infection.

These volunteers initially received one dose of the vaccine and then a new booster dose after four weeks.

Tomas Hanke, professor of vaccine immunology at Oxford University's Jenner Institute and lead researcher on the trial, said: “An effective HIV vaccine has been elusive for 40 years.

"This trial is the first in a series of evaluations of this new vaccine strategy in HIV-negative individuals for prevention and in people living with HIV who can be cured."

How it works

While most HIV vaccine candidates work by inducing antibodies generated by B cells, HIVconsvX induces immune system T cells.

It attacks highly conserved and therefore vulnerable regions of HIV – an “Achilles' heel” common to most HIV variants.

Results

The trial is part of the European Aids Vaccine Initiative (EAVI2020), an international collaborative research project funded by the European Commission under the Horizon 2020 health program for research and innovation.

The researchers hope to be able to report test results by April next year.


Comentários
0 comentários


  • Enviar Comentário
    Para Enviar Comentários é Necessário estar Logado.
    Clique Aqui para Entrar ou Clique Aqui para se Cadastrar.

Ainda não Foram Enviados Comentários!
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO

Copyright 2021 - Jornal Pacifista - Todos os direitos reservados. powered by WEB4BUSINESS

Inglês Português Frances Italiano Alemão Espanhol Árabe Bengali Urdu Esperanto Croata Chinês Coreano Grego Hebraico Japonês Hungaro Latim Persa Polonês Romeno Vietnamita Swedish Thai Czech Hindi Você